Emerging Roles of miRNA, lncRNA, circRNA, and Their Cross-Talk in Pituitary Adenoma

Wentao Wu; Lei Cao; Yanfei Jia; Youchao Xiao; Xu Zhang; Songbai Gui

doi:10.3390/cells11182920

Emerging Roles of miRNA, lncRNA, circRNA, and Their Cross-Talk in Pituitary Adenoma

Cells. 2022 Sep 19;11(18):2920. doi: 10.3390/cells11182920.

Authors

Wentao Wu¹, Lei Cao¹, Yanfei Jia¹, Youchao Xiao¹, Xu Zhang², Songbai Gui¹

Affiliations

¹ Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 119 South Forth West Ring, Beijing 100070, China.
² Department of Oncology, First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Hefei 230032, China.

Abstract

Pituitary adenoma (PA) is a common intracranial tumor without specific biomarkers for diagnosis and treatment. Non-coding RNAs (ncRNAs), including microRNAs (miRNA), long non-coding RNA (lncRNA), and circular RNA (circRNA), regulate a variety of cellular processes, such as cell proliferation, differentiation, and apoptosis. Increasing studies have shown that the dysregulation of ncRNAs, especially the cross-talk between lncRNA/circRNA and miRNA, is related to the pathogenesis, diagnosis, and prognosis of PA. Therefore, ncRNAs can be considered as promising biomarkers for PA. In this review, we summarize the roles of ncRNAs from different specimens (i.e., tissues, biofluids, cells, and exosomes) in multiple subtypes of PA and highlight important advances in understanding the contribution of the cross-talk between ncRNAs (e.g., competing endogenous RNAs) to PA disease.

Keywords: biomarker; ceRNA; non-coding RNA; pathogenesis; pituitary adenomas.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers
Cell Proliferation
Humans
MicroRNAs* / genetics
Pituitary Neoplasms* / genetics
RNA, Circular / genetics
RNA, Long Noncoding* / genetics
RNA, Untranslated / genetics

Substances

Biomarkers
MicroRNAs
RNA, Circular
RNA, Long Noncoding
RNA, Untranslated

Grants and funding

S.G. was supported by the Beijing Municipal Science & Technology Commission (Z19110700660000) and Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support (XMLX202108). X.Z. was supported by the National Natural Science Foundation of China (82100628), the Natural Science Foundation of Anhui Province (2108085QH313), the Postdoctoral Science Foundation of China (2021M700183), and the Postdoctoral Science Foundation of Anhui Province (2021B496).